EU Funding

"Soraprazan": A STGD POC study

Together with a consortium of six partners, Katairo has received funding from the European Commission.

Under the project name "Soraprazan" - which is the INN name of the active ingredient of Remofuscin - a proof-of-concept clinical trial with Remofuscin for Stargardt disease is being prepared and performed. 

The project includes the manufacture of the drug product including trial site supply, attention to regulatory affairs, the planning and performing of the clinical study managed by an industry CRO, the setting-up and maintenance of a pharmacovigilance system, the communication and dissemination of results, the preparation of the exploitation of results and the coordination of the project. 

The clinical trial is scheduled to start in Q4 2018 and last through late 2021. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 779317.

If you are interested in updates on this program, please subscribe to our news-letter.

Consortium

The consortium includes the following partners

Eberhard-Karls-Universität Tübingen
(coordinator, trial site)
Radboud University Medical Center, Nijmegen
(trial site)
Ospedale San Rafaele, Milano
(trail site)
Leiden University Medical Center
(trial site)
Southhampton University Hospital
(trial site)
Smerud Medical Research, Oslo
(clinical research organisation)
Katairo
(sponsor)